Stock Financial Ratios, Dividends, Split History

FRED / Fred's, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)66.52
Enterprise Value ($M)225.46
Book Value ($M)160.29
Book Value / Share4.30
Price / Book0.30
NCAV ($M)-43.73
NCAV / Share-1.17
Price / NCAV-1.96
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 37,392
Weighted Average Number Of Diluted Shares Outstanding 37,392
Common Shares Outstanding2 0
Common Shares Outstanding 37,127,059
Scoring Models
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.77
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Quick Ratio0.42
Current Ratio1.66
Income Statement (mra) ($M)
Sales Revenue Net1,805,405,000.00
Franchise Revenue700,000.00
Disposal Group Including Discontinued Operation Revenue275,952,000.00
Operating Income-131.73
Net Income-150.19
Earnings Per Share Diluted-4.02
Earnings Per Share Basic-4.02
Cash Flow Statement (mra) ($M)
Cash From Operations-18.42
Cash from Investing-15.15
Cash from Financing-15.15
Identifiers and Descriptors
Central Index Key (CIK)724571
Related CUSIPS
356108900 356108950
Industry Groups
SIC 5331 - Variety Stores

Split History

Stock splits are used by Fred's, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Fred's, Inc. (FRED) CEO Joe Anto on Q1 2018 Results - Earnings Call Transcript

2018-06-14 seekingalpha
Good morning, everyone and thank you for attending today’s conference call to review Fred’s Financial Results for the First Quarter ended May 5, 2018. Joining us today are Fred’s Interim CEO and Chief Financial Officer, Joe Anto as well as Fred’s External IR Advisor, Sean McGowan of Liolios. Instructions will be given at the end of the call for follow-up discussions with management. (2-1)

Fred's Confirms Sale of Specialty Pharmacy Unit, Stock Up

2018-05-08 zacks
Fred’s Inc. confirmed sale of certain assets of its specialty pharmacy business, EntrustRx, to CVS Health Corporation (CVS - Free Report) . The company has been considering the divesture of its specialty pharmacy unit for a while, in a bid to monetize non-core assets, reduce debt load and induce a turnaround in its operations. Per the terms, Fred’s is entitled to receive $40 million along with a sum equivalent to EntrustRx’s inventory value. (140-0)

Fred's (FRED) Q4 Loss Widens Year Over Year, Stock Loses 6%

2018-05-07 zacks
Fred’s Inc. released fourth-quarter fiscal 2017 results, wherein both the top and bottom line deteriorated year on year. Shares of the company lost 6.3% on May 4, following the dismal performance. In fact, the company has lost almost 89% in a year, as against the industry’s 17.3% growth. This is largely attributable to Fred’s dismal comps and earnings record, as well as the impact of the canceled merger between Rite Aid (RAD - Free Report) and Walgreens (WBA - Free Report) . (139-0)

Fred's (FRED) CEO Joseph Anto on Q4 2017 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good morning, everyone, and thank you for attending today's conference call to review Fred's Financial Results for the Fourth Quarter and Fiscal Year Ended February 3, 2018. (2-0)

Fred's Stock Jumps Over 13% in a Day, 2 Things You Must Note

2018-04-18 zacks
Investors are keeping a close watch on Fred’s Inc. as the discount retailer is gearing up to report fourth-quarter fiscal 2017 results. However, there are two things investors must note before they take a stock of the results. Firstly, Fred’s has rescheduled its earnings announcement date, and the second thing to note is why the company took this step. Well, Fred’s revealed that its fourth-quarter earnings are now slated to be reported on May 4, which will be followed by management’s conference call. (180-1)

CUSIP: 356108100